Search | TVST | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 9 of 9

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Clinical Trials June 2022

Topical Ocular Anti-TNFα Agent Licaminlimab in the Treatment of Acute Anterior Uveitis: A Randomized Phase II Pilot Study

PDF

Theodore A. Pasquali; Melissa M. Toyos; David B. Abrams; David K. Scales; John W. Seaman, III; Georges Weissgerber
TAGS: dexamethasone, pilot projects, uveitis, anterior, uveitis, safety
Trans. Vis. Sci. Tech.. 2022; 11(6):14. https://doi.org/10.1167/tvst.11.6.14

ARVO Annual Meeting Abstract June 2022

Comparison of Near and Distance Visual Acuity Measured via ETDRS Charts in neovascular Age-related Macular Degeneration and Diabetic Macular Edema Study Participants Managed with Anti-VEGF Therapy

Kira Lin; Onnisa Nanegrungsunk; Guillaume Normand; Susan B Bressler; Daniele Dolis; Lieve Convents; John Seaman; Kang Yan; Georges Weissgerber; Guy Simpson; Michael J Elman; Hani Salehi-Had; Andres Emanuelli; Zhuolin Li; Neil M Bressler

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1397 – A0093.

ARVO Annual Meeting Abstract June 2020

Disease Activity Assessments with Brolucizumab vs Aflibercept in Patients with nAMD in HAWK and HARRIER

Rishi P Singh; Robin Hamilton; Jeffrey S Heier; Carl Regillo; Mark C Gillies; Georges Weissgerber; Jahangir Alam; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1158.

ARVO Annual Meeting Abstract June 2020

A comparison of the therapeutic response between brolucizumab and aflibercept in the HAWK & HARRIER trials using deep learning-based OCT analysis

Ursula Schmidt-Erfurth; Zufar Mulyukov; Bianca S S. Gerendas; Philippe Margaron; Daniel Lorand; Hrvoje Bogunovic; Georges Weissgerber

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1159.

ARVO Annual Meeting Abstract July 2019

Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER

Rishi P Singh; Charles Clifton Wykoff; Ramin Tadayoni; Yuichiro Ogura; Adrian H C Koh; Frank G Holz; Robin Hamilton; David Tanzer; Georges Weissgerber; Jahangir Alam; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5194.

ARVO Annual Meeting Abstract July 2019

Prediction of Geographic Atrophy progression by deep learning applied to retinal imaging

Guillaume Normand; Gwenole Quellec; Ronan Danno; Bruno Lay; Georges Weissgerber; Nadia Zakaria; Sudeep Chandra

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1452.

ARVO Annual Meeting Abstract July 2018

Topical VEGF receptor inhibitor, LHA510, did not demonstrate efficacy in a Proof-of-Concept study in patients with neovascular age-related macular degeneration (nv AMD)

Stephen H Poor; Christopher M Adams; Michael Ferriere; Andreas Weichselberger; Cynthia L Grosskreutz; Georges Weissgerber

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2394.

ARVO Annual Meeting Abstract June 2017

Validation of 3D volumetry for a novel anti-angiogenic therapy of neovascular age-related macular degeneration

Guillaume Normand; Eric H SOUIED; Bruno Lay; Ronan Danno; Rocio Blanco-Garavito; Perrinne Charrard; Jordan Harrod; Michael Maker; Sudeep Chandra; Georges Weissgerber

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1282.

ARVO Annual Meeting Abstract March 2012

Safety And Tolerability Of Single Escalating Doses Of Esba1008, A Single-chain Anti-vegf Antibody Fragment, In Patients With Exudative Age-related Macular Degeneration

Georges Weissgerber; Sushanta Mallick; Esteve Travesa; Colin Hughson; Thomas Valencia; Hermann Schulze; Kyounghwa Bae; Silvia Boller; Anne Schmidt; Dominik Escher

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):4641.

Advertisement